Abbott India
Market Cap
₹231.7b
Last Updated
2019/10/16 12:35 UTC
Data Sources
Company Financials +
Executive Summary
Abbott India Limited operates as a pharmaceutical company in India.
Snowflake
Fundamentals
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Abbott India's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.5%
500488
1.4%
IN Pharmaceuticals
1.4%
IN Market
1 Year Return
49.5%
500488
-20.0%
IN Pharmaceuticals
2.3%
IN Market
Return vs Industry: 500488 exceeded the Indian Pharmaceuticals industry which returned -20% over the past year.
Return vs Market: 500488 exceeded the Indian Market which returned 2.3% over the past year.
Shareholder returns
| 500488 | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.5% | 1.4% | 1.4% |
| 30 Day | 11.2% | -7.1% | 2.7% |
| 90 Day | 27.9% | -5.2% | -1.4% |
| 1 Year | 50.6%49.5% | -19.3%-20.0% | 4.3%2.3% |
| 3 Year | 137.0%131.3% | -27.3%-28.8% | 20.9%14.9% |
| 5 Year | 268.5%254.5% | -11.9%-14.6% | 41.2%28.2% |
Price Volatility Vs. Market
How volatile is Abbott India's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
June Top Growth Stocks To Look Out For1 year ago | Simply Wall St
June Top Growth Stocks To Look Out For1 year ago | Simply Wall St
June Top Growth Stocks To Look Out ForValuation
Is Abbott India undervalued compared to its fair value and its price relative to the market?
47.92x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: 500488 (₹10935.3) is trading above our estimate of fair value (₹4019.93)
Significantly Undervalued: 500488 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500488 is poor value based on its PE Ratio (47.9x) compared to the Pharmaceuticals industry average (15.6x).
PE vs Market: 500488 is poor value based on its PE Ratio (47.9x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
Low PEG Ratio: 500488 is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: 500488 is overvalued based on its PB Ratio (11.6x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Abbott India forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
14.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500488's forecast earnings growth (14.9% per year) is above the savings rate (7.6%).
Earnings vs Market: 500488's earnings (14.9% per year) are forecast to grow slower than the Indian market (18.1% per year).
High Growth Earnings: 500488's earnings are forecast to grow, but not significantly.
Revenue vs Market: 500488's revenue (11.2% per year) is forecast to grow slower than the Indian market (11.4% per year).
High Growth Revenue: 500488's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if 500488's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Abbott India performed over the past 5 years?
18.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 500488's earnings have grown by 18.1% per year over the past 5 years.
Accelerating Growth: 500488's earnings growth over the past year (11.4%) is below its 5-year average (18.1% per year).
Earnings vs Industry: 500488 earnings growth over the past year (11.4%) underperformed the Pharmaceuticals industry 14.4%.
Return on Equity
High ROE: 500488's Return on Equity (24.1%) is considered high.
Return on Assets
ROA vs Industry: 500488 has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 500488 has improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Abbott India's financial position?
Financial Position Analysis
Short Term Liabilities: 500488's short term assets (₹27.6B) exceeds its short term liabilities (₹8.6B)
Long Term Liabilities: 500488's short term assets (27.6B) exceeds its long term liabilities (754.3M)
Debt to Equity History and Analysis
Debt Level: 500488 is debt free.
Reducing Debt: 500488 has not had any debt for past 5 years.
Debt Coverage: 500488 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500488 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: 500488 has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 500488's debt is covered by short term assets.
Next Steps
Dividend
What is Abbott India's current dividend yield, its reliability and sustainability?
0.59%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 500488's dividend (0.59%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.61%).
High Dividend: 500488's dividend (0.59%) is low compared to the top 25% of dividend payers in the Indian market (2.51%).
Stable Dividend: 500488's dividends per share have been stable in the past 10 years.
Growing Dividend: 500488's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (21.9%), 500488's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of Abbott India's salary, the management and board of directors tenure and is there insider trading?
1.8yrs
Average board tenure
CEO
Ambati Venu (50yo)
3.1yrs
Tenure
₹65,075,000
Compensation
Mr. Ambati Venu has been Managing Director at Abbott India Limited since September 29, 2016. Mr. Venu served as Executive Vice President and General Manager of Sales Eastern Region of Glaxosmithkline Consu ...
CEO Compensation Analysis
Compensation vs. Market: Ambati's total compensation ($USD910.33K) is about average for companies of similar size in the Indian market ($USD822.55K).
Compensation vs Earnings: Ambati's compensation has been consistent with company performance over the past year.
Board Age and Tenure
1.8yrs
Average Tenure
60yo
Average Age
Experienced Board: 500488's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Ambati Venu (50yo)
MD & Executive Director
- Tenure: 3.1yrs
- Compensation: ₹65.08m
Rajiv Sonalker (60yo)
CFO, Group Finance Director & Whole-time Director
- Tenure: 2.2yrs
- Compensation: ₹30.48m
Krupa Anandpara
Associate Director - Secretarial
- Tenure: 0yrs
- Compensation: ₹6.83m
Mike Warmuth (56yo)
Executive Vice President of Pharmaceuticals Division
- Tenure: 0yrs
Keya Phatnani
Associate Director of Human Resources
- Tenure: 0yrs
Board Members
Ambati Venu (50yo)
MD & Executive Director
- Tenure: 3.1yrs
- Compensation: ₹65.08m
Rajiv Sonalker (60yo)
CFO, Group Finance Director & Whole-time Director
- Tenure: 2.2yrs
- Compensation: ₹30.48m
Munir Shaikh (76yo)
Chairman of the Board
- Tenure: 0yrs
- Compensation: ₹1.50m
Kaiyomarz Marfatia (63yo)
Non-Executive Director
- Tenure: 8.6yrs
- Compensation: ₹15.90m
Sudarshan Jain (64yo)
Independent Director
- Tenure: 0.5yrs
- Compensation: ₹5.94m
Anisha Motwani (56yo)
Independent Director
- Tenure: 1.5yrs
- Compensation: ₹1.30m
Krishna Sahni (72yo)
Independent Director
- Tenure: 5yrs
- Compensation: ₹1.45m
Mark Murphy (51yo)
Non-Executive Director
- Tenure: 0.5yrs
Jawed Zia (56yo)
Non-Executive Director
- Tenure: 1.3yrs
Company Information
Abbott India Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Abbott India Limited
- Ticker: 500488
- Exchange: BSE
- Founded: 1944
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹231.694b
- Shares outstanding: 21.25m
- Website: https://www.abbott.co.in
Number of Employees
Location
- Abbott India Limited
- Godrej BKC
- 16th Floor, Plot C- 68, “G” Block
- Mumbai
- Maharashtra
- 400051
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 500488 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Sep 1999 |
| ABBOTINDIA | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Sep 1999 |
Biography
Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women’s health, gastroenterology, metabolics, central nervous sy ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/16 12:35 |
| End of Day Share Price | 2019/10/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.